We describe a patient presenting with systemic lupus eryral and pericardial effusions, multiple pulmonary infiltrates thematosus (SLE) and concomitant low-grade (lg) non-Hodgand intraabdominal lymphadenopathy. was repeatedly negative. Hepatitis B serology indicated former
infection without chronicity. CMV IgG and IgM ELISA were positive, suggesting CMV reactivation. CMV was isolated from peripheral blood.
Introduction
High-titer antinuclear antibodies (ANA) (1:10240) and antidouble stranded DNA (anti-dsDNA) antibodies (227 U/l) in The coexistence of lymphoproliferative and autoimmune discombination with reduced C3, C4 and CH100 activity were orders is well known. 1 For instance, there are reports on the observed. The diagnosis of systemic lupus erythematosus was simultaneous occurrence of both Hodgkin's and non-Hodgmade according to the criteria of the American Rheumatism kin's lymphoma in autoimmune disorders such as primary Association. 8 The following criteria were observed: discoid Sjö gren's syndrome (SS), 2, 3 rheumatoid arthritis (RA) 3, 4 and rash, arthritis, serositis, renal disorder (proteinuria), hematosystemic lupus erythematosus (SLE). 5, 6 In the cases reported logic disorder (leukopenia, thrombopenia), immunologic disthus far the autoimmune disorder preceded the onset of order (positive anti-dsDNA antibodies) and positive ANAs. lymphoid malignancy by several years. [2] [3] [4] [5] Lymphoma may Renal biopsy revealed mesangial lupus glomerulonephritis develop after immunosuppressive therapy 4, 5, 7 but may also (WHO type II). Iliac crest biopsy showed slightly hypercellular occur without prior treatment. 2 In this report, we describe the bone marrow with reduced erythropoiesis and focal infilobviously rare event of SLE and low-grade CD5 + B-NHL simtration by low-grade non-Hodgkin's lymphoma ( Figure 1 ). The ultaneously diagnosed in a patient. The role of the CD5 + B lymphoma was diagnosed as low-grade malignant by a refercell subset in the development and activity of autoimmune ence hematopathologist (Professor A Feller, Department of disease is discussed and possible pathogenetic links in the Pathology, University of Lü beck, Germany). Immunophenodevelopment of concomitant lymphoma are reviewed. 
/CD19
+ popuCase report lation comprised 50% of all gated lymphocytes. ␤2 microglobulin was elevated (20.4 mg/l). A clonal immuno-A 40-year-old patient was admitted because of fever, dyspnea, globulin heavy chain gene rearrangement was found both in lymphadenopathy and systemic rash. The former history was PBMC and bone marrow by PCR ( Figure 2 ). unremarkable, except for hepatitis B infection in 1988. On
The patient was started on prednisolone (2 mg/kg) and admission the patient was febrile (38.6°C) and a generalized cyclophosphamide (150 mg/day). Clinical symptoms and SLE discoid rash was noted. There was no purpura or ekchymosis.
disease activity subsided within 4 weeks. Three months after However, generalized lymphadenopathy, moderate hepatothe start of therapy steroids were discontinued. Renal and hepsplenomegaly and edema were found. CT Giemsa stain of patient's bone marrow biopsy demonstrating infiltration with a small lymphocyte population consistent with the diagnosis of low grade malignant NHL (× 875).
Figure 2
Persisting clonal immunoglobulin heavy chain rearrangement as shown by IgH CDR III PCR using V H and J H primers. Lanes 2 and 3: bone marrow at first diagnosis; lane 4: peripheral blood mononuclear cells (MNC) at first diagnosis; lane 5: MNC 24 months after first diagnosis. Lanes 1 and 6: molecular size markers.
to disease activity. After 2 years of treatment immuno-phenotyping of peripheral blood mononuclear cells did not reveal a persisting monoclonal CD5 + /CD19 + lymphocyte population and the spleen had returned to a normal size. Similarly, lymph nodes were found not to be enlarged at that time. However, the monoclonal IgH rearrangement persisted (Figure 2 ), indicating residual disease. Serum LDH was repeatedly within the normal range. The patient refused further bone marrow biopsies. Currently there are no clinical signs of lupus activity disease. Top: anti-dsDNA antibody titers (circles) and serum creatinine (squares) as markers of SLE disease activity. Bottom: sIL-2R level (squares, dashed line) and IL-3 levels (circles).
Discussion
In this report a patient is presented diagnosed with SLE simuldiagnosis of B-NHL was based on: (1) the presence of a monoclonal CD5 + /CD19 + population of lymphocytes in the periphtaneously occurring with a low-grade NHL. SLE was diagnosed according to the standard criteria of the American eral blood; (2) biopsy-proven focal bone marrow infiltration by small lymphoid cells compatible with low-grade malignant Rheumatism Association (ARA). 8 A discoid rash, arthritis, serositis, renal disorder (proteinuria), hematologic disorder (both NHL; and (3) a clonal rearrangement of immunoglobulin heavy chain genes both in the peripheral blood and bone leukopenia and thrombopenia) and positivity of ANAs and anti-dsDNA antibodies clearly established the diagnosis. The marrow.
Although never studied in detail, an association between Is there a common background for the manifestation of SLE and monoclonal proliferation of CD5 + B cells seen in our lymphoproliferative disorders and autoimmune disease has been well established. In most cases the autoimmune disease precedes the onset ease and lymphoma in humans is suggested by the studies of Conley et al 31 and Kipps and Vaughan. 32 Conley et al 31 of lymphoma by several years. In patients diagnosed with an autoimmune disease, the subsequent development of lymdescribed an increased incidence of autoimmune diseases including SLE, in relatives of CLL patients. Kipps and phoma is not dependent on previous immunosuppressive treatment. 2 The simultaneous manifestation of SLE and lymVaughan 32 discussed a genetic influence on the level of CD5 + lymphocytes in peripheral blood. The pathogenesis of genetic phoma seems to be a very rare event. 2, 6 On the other hand, autoimmune phenomena are frequent in low-grade NHL. 9 susceptibility to both disorders is still unresolved as yet. However, experimental data infer that related major histocompatAutoimmune hemolytic anemia complicates CLL in one third of patients over the course of the disease.
13 Interestingly, the ibility complex (MHC) haplotypes predispose to either B-CLL or autoimmune disease and could account for the high inciwarm autoantibodies are normally not produced by the malignant clone of B cells, distinguishing this complication from dence of autoimmune disease including SLE, in relatives of patients with CLL.
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cold agglutinin disease and cryoglobulinemia. 14,15 CD5 + B cells comprise 10-25% of circulating and splenic B lympho-A second line of evidence suggests that altered production of cytokines might be involved in the development of both cytes in adults 16 and are the majority of B cells in human cord blood and fetal spleen 17 where they represent a specific B cell disease conditions. 33-35 Interleukin-4 (IL-4) bears the potential to inhibit both rheumatoid factor production and CD5 subset implicated in establishing the immune system repertoire, immunoregulation, processing and presentation of antiexpression in RA patients. 34 It may also suppress proliferation and differentiation of B cells. 36 Thus, decreased IL-4 progen and production of 'natural autoantibodies' (reviewed in Ref. 13 ). An intriguing feature of autoimmune disorders such duction might be involved in expansion of CD5 + lymphocytes and SLE activity. However, IL-4 levels measured in the as RA and SS is the polyclonal expansion of the CD5 + B cell subset, 18 yet the number of circulating CD5 + B cells is indepatient's serum did not correlate with disease activity (data not shown). Production and serum levels of IL-3 are increased pendent of disease activity in these disorders. In SLE the number of CD5 + B cells is in general not increased, 19 although in SLE patients. 35 In a cohort of SLE patients, highest levels were found in two patients with concomitant lymphoma. 35 ILthere are some reports on elevated CD5
+ B cell levels in some patients [20] [21] [22] without any correlation with disease activity. 20 3 acts as a growth factor in normal B cells and lymphoma. 37, 38 These data are in line with observations in SLE prone MRL/lpr Although there is some evidence for an involvement of the CD5 + B cell subset in autoimmunity, a causative role for this mice. These animals frequently display lymphoid hyperplasia and high IL-3 activity in serum. However, IL-3 measurements B cell population has not been established (reviewed in Ref. 23). Two types of autoantibodies to ssDNA can be isolated revealed baseline levels that did not parallel disease activity in our patient ( Figure 3 ). from sera of SLE patients. The first type belongs to the IgM class, is polyreactive and binds DNA with moderate affinity.
Thirdly, there are reports of a deregulated response to cytokines in SLE and lymphoma. SLE prone NZB/W F1 mice carry This type of antibody, which is similar to the 'natural' polyreactive autoantibodies inducible in the repertoire of healthy a high number of IL-2 hyperresponsive B cells, the majority being Ly-1 + . Enhanced IL-2 expression by injection of IL-2 human subjects by polyclonal activation is produced mainly by CD5 + B cells. The monoreactive antibodies binding ssDNA expression vectors into skeletal muscle of lupus prone MRL/lpr/lpr mice results in increased auto-antibody prowith high affinity belong to the IgA or IgG class and are mainly produced by CD5 − B lymphocytes. 19 The latter type of antiduction. 39 The response to IL-2 is dependent on the expression of IL-2 receptor (IL-2R, CD25). IL-2R is expressed and released bodies displays features seen in 'mature' antigen-driven immune responses. Therefore, an antigen driven process of predominantly by activated T lymphocytes. There are several reports on elevated sIL-2R levels in SLE patients with active positive selection and somatic mutation might 'shape' the anti-self response in autoimmune diseases. 17, 24, 25 disease. [40] [41] [42] [43] [44] [45] Elevated levels are not due to diminished clearance of sIL-2R. 42 sIL-2R levels are elevated in SLE patients This hypothesis is supported by experimental data gained from a murine model 26, 27 and an EBV-transformed human cell even without active disease. 44 On the other hand, sIL-2R levels correlate with disease activity in B-NHL 46 ,47 even though line. 28 In autoimmune MRL/lpr mice, the V gene segments encoding anti-ssDNA antibodies and rheumatoid factors con-CD25 expression in lymphocytes of NHL patients is not different from control individuals. 46 In our patient we observed high tain a multitude of somatic mutations. However, anti-ssDNA antibodies have less biological significance than anti-dsDNA basal sIL-2R levels that correlated both with SLE and NHL activities ( Figure 3) . Thus, increased sIL-2R levels most likely antibodies. The origin of anti-dsDNA antibodies in SLE patients has not been attributed to CD5 + or CD5 − B cells as reflect a state of polyclonal T cell activation that might link both diseases as CD25 expression by clonal CD5 + B lymphoyet. The high-affinity anti-dsDNA antibodies secreted by an EBV-transformed human B cell line is encoded by gene segcytes was not examined. Therefore, high CD25 expression and release by CD5 + B lymphocytes cannot be ruled out at ments showing multiple somatic mutations. Therefore, according to these data, the secretion of high-affinity antithis time. Recent data by Chen et al 48 provide the basis for a fourth ssDNA and anti-dsDNA antibodies are characteristic of an antigen-driven immune response. However, antibodies prohypothesis that links the pathogenesis of SLE and NHL. Using a transgenic mouse model for the heavy chain of an anti-DNA duced by CLL cells are encoded by germline V genes with little or no somatic mutations. 13 Taken together, there is no antibody from an autoimmune MRL/lpr mouse, Chen showed that B cell clones producing anti-DNA antibodies are deleted evidence for CD5
+ lymphocytes producing pathogenic autoantibodies in SLE in humans.
in the bone marrow of non-autoimmune mice. The anti-DNA 
